anvylic-3288
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01851603)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Neuronal acetylcholine receptor protein alpha-7 subunitPOSITIVE ALLOSTERIC MODULATOR
CHRNA7 positive allosteric modulator
Type I positive allosteric modulator.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(/C(=C/Nc2ccc(Cl)cc2)C(=O)Nc2ccc(Cl)cc2)on1- Mol. weight
- 388.25 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL429317 ↗
Also known as
- anvylic-3288
- anvylic-3288
- avl-3288
- avl-3288
- avl-3288
- ccmi
- ccmi
- uci-4083
- uci-4083
- xy-4083
- xy-4083
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02978599 | Phase 1 | Nov 1, 2016 | Columbia University, National Institute of Mental Health (NIMH) |
| NCT01851603 | Phase 1 | Jun 1, 2013 | National Institute of Mental Health (NIMH), University of Colorado, Denver |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 2 | 0 | 1 | 2013 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1